Investor Presentaiton
Immunology
LPA₁
Sotyktu
CD19 NEX T
Compelling CART data in lupus supports expanding new
modality to address unmet need
Potential transformational efficacy and favorable safety demonstrated with CD19 CAR T
Disease Remission Post CART Treatment¹
SLEDAI
Data Suggests Immune System Reset²
Before CAR T
After CAR T
Before CAR T
After CAR T
20
100%
20
100%
15
80%
15
All patients achieved
complete remission
60%
10
10
5
5
40%
Remission
20%
0 0 0 0 0 0 0
■Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6 Pt. 7
80%
60%
40%
20%
0%
0%
Pt. 1
Pt. 2
Pt. 3
Pt. 4
Pt. 5
Pt. 1
Pt. 2
Pt. 3 Pt. 4
Pt. 5
■Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6 Pt. 7
7/7 pts achieved durable DORIS complete remission off all
therapy; encouraging safety & tolerability with only grade 1
cytokine release syndrome and no neurotoxicity
Patient immune system reset after CAR T treatment:
Measurement of immunoglobulins shift from mature B-cells
expressing IgA & IgG to naïve B-cells expressing IgM & IgD
IgD
■IgM
IgA
IgG
Ill Bristol Myers Squibb™
1. Adapted from Taubmann, J., et al EULAR (2023): 93-94. 2. Adapted from Mackensen, A., Müller, F., Mougiakakos, D. et al. Nat Med 28, 2124-2132 (2022)
Not for Product Promotional Use
68View entire presentation